NCT06444009View on ClinicalTrials.gov

A Phase II Study of Neoadjuvant Immunotherapy in Combination With Chemotherapy in Locally Advanced Head and Neck Squamous Cell Carcinoma

PHASE2RecruitingINTERVENTIONAL
Enrollment

90

Participants

Timeline

Start Date

July 1, 2024

Primary Completion Date

December 1, 2025

Study Completion Date

December 1, 2027

Conditions
Head and Neck Squamous Cell Carcinoma
Interventions
DRUG

Ivonescimab combined with TP

Both interventions all drugs intravenous infusion, D1, once every 3 weeks, a total of 3 cycles.

DRUG

Cadonilimab combined with TP

Both interventions all drugs intravenous infusion, D1, once every 3 weeks, a total of 3 cycles.

DRUG

Penpulimab combined with TP

Both interventions all drugs intravenous infusion, D1, once every 3 weeks, a total of 3 cycles.

Trial Locations (1)

Unknown

RECRUITING

West China Hospital, Chengdu

All Listed Sponsors
lead

Lei Liu

OTHER